Hematology Division
Alphabetical list (active faculty):   
Morey A. Blinder

Morey A. Blinder, MD


Department of Medicine

Hematology Division

Department of Pathology & Immunology

Clinical Interests

  • Disorders of iron metabolism
  • Sickle cell disease
  • Immune-mediated hematologic disease
  • Bleeding and thromboembolic disorders

Research Interests

  • Treatment of iron overload disorders and iron deficiency
  • Management of sickle cell disease
  • Treatment of ITP and TTP


  • 314-362-8814 (office)
  • 314-696-1391 (fax)
  • Hematology Division
    Mail Stop 8125-0022-01
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • Suite 1101 Wohl Hospital (office)

Peer-reviewed Manuscripts

  • Silent Infarcts, White Matter Integrity, and Oxygen Metabolic Stress in Young Adults With and Without Sickle Cell Trait
    Wang Y, Guilliams KP, Fields ME, Fellah S, Binkley MM, Reis M, Vo KD, Chen Y, Ying C, Blinder M, King AA, Hulbert ML, An H, Lee JM, Ford AL
    Stroke 2022 Sep;53(9):2887-2895
  • Quality of Life After Pharmacomechanical Catheter-Directed Thrombolysis for Proximal Deep Venous Thrombosis
    Kahn SR, Julian JA, Kearon C, Gu CS, Cohen DJ, Magnuson EA, Comerota AJ, Goldhaber SZ, Jaff MR, Razavi MK, Kindzelski AL, Schneider JR, Kim P, Chaer R, Sista AK, McLafferty RB, Kaufman JA, Wible BC, Blinder M, Vedantham S
    ATTRACT Trial Investigators

    J Vasc Surg Venous Lymphat Disord 2020 Jan;8(1):8-23e18
  • A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
    Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J
    HOPE Trial Investigators (Contributors include: Blinder M)

    N Engl J Med 2019 Aug 8;381(6):509-519
  • Hydroxyurea Reduces Cerebral Metabolic Stress in Patients With Sickle Cell Anemia
    Fields ME, Guilliams KP, Ragan D, Binkley MM, Mirro A, Fellah S, Hulbert ML, Blinder MA, Eldeniz C, Vo K, Shimony JS, Chen Y, McKinstry RC, An H, Lee JM, Ford AL
    Blood 2019 May 30;133(22):2436-2444
  • Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
    Scully M, Cataland SR, Peyvandi F, Coppo P, Knobl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK
    HERCULES Investigators (Contributors include: Blinder M)

    N Engl J Med 2019 Jan 24;380(4):335-346
  • Plasmapheresis for Management of Antiphospholipid Syndrome in the Neurosurgical Patient
    Arias EJ, Bruck B, Vellimana AK, Eby C, Reynolds MR, Blinder MA, Zipfel GJ
    Oper Neurosurg (Hagerstown) 2019 Apr 1;16(4):E124-E129
  • Adherence to Iron Chelation Therapy in Patients Who Switched From Deferasirox Dispersible Tablets to Deferasirox Film-Coated Tablets
    Cheng WY, Said Q, Hao Y, Xiao Y, Vekeman F, Bobbili P, Duh MS, Nandal S, Blinder M
    Curr Med Res Opin 2018 Nov;34(11):1959-1966
  • Acute Graft-Versus-Host Disease Following Lung Transplantation in a Patient With a Novel TERT Mutation
    Brestoff JR, Vessoni AT, Brenner KA, Uy GL, DiPersio JF, Blinder M, Witt CA, Byers DE, Hachem RR, Truclock EP, Early DS, Anadkat MJ, Musiek A, Javidan-Nejad C, Balfe DM, Rosman IS, Liu C, Zhang L, Despotis GJ, Ruzinova MB, Sehn JK, Amarillo I, Heusel JW, Swat W, Kim BS, Wartman LD, Yusen RD, Batista LFZ
    Thorax 2018 May;73(5):489-492
  • Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis
    Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, Magnuson E, Razavi MK, Comerota AJ, Gornik HL, Murphy TP, Lewis L, Duncan JR, Nieters P, Derfler MC, Filion M, Gu CS, Kee S, Schneider J, Saad N, Blinder M, Moll S, Sacks D, Lin J, Rundback J, Garcia M, Razdan R, VanderWoude E, Marques V, Kearon C
    ATTRACT Trial Investigators

    N Engl J Med 2017 Dec 7;377(23):2240-2252
  • Combination Therapy in Relapsed or Refractory Chronic Immune Thrombocytopenia: A Case Report and Literature Review
    Rashidi A, Blinder MA
    J Clin Pharm Ther 2016 Oct;41(5):453-8
  • Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
    Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knobl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D (Investigators include: Blinder M)
    N Engl J Med 2016 Feb 11;374(6):511-22
  • Age-Related Emergency Department Reliance in Patients With Sickle Cell Disease
    Blinder MA, Duh MS, Sasane M, Trahey A, Paley C, Vekeman F
    J Emerg Med 2015 Oct;49(4):513-522e1
  • Exertional Sickling: Questions and Controversy
    Blinder MA, Russel S
    Hematol Rep 2014 Dec 3;6(4):5502
  • Systemic Effects of Subcutaneous Heparin Use in Otolaryngology Patients
    Blank SJ, Grindler DJ, Zerega J, Blinder M, Nussenbaum B
    Otolaryngol Head Neck Surg 2014 Dec;151(6):967-71
  • Cutaneous Manifestations of Sickle Cell Disease
    Jones H, Blinder M, Anadkat M
    Open Journal of Blood Diseases 2013;3:94-99
  • Age-Related Treatment Patterns in Sickle Cell Disease Patients and the Associated Sickle Cell Complications and Healthcare Costs
    Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS
    Pediatr Blood Cancer 2013 May;60(5):828-835
  • Successful Orthotopic Liver Transplantation in an Adult Patient With Sickle Cell Disease and Review of the Literature
    Blinder MA, Geng B, Lisker-Melman M, Crippin JS, Korenblat K, Chapman W, Shenoy S, Field JJ
    Hematol Rep 2013 May 2;5(1):1-4
  • Effect of New Anticoagulant Drugs on Coagulation Testing
    Schmidt AE, Blinder MA
    ASCP Case Reports: Hematopathology 2013
  • Platelet Point-Of-Care Testing
    Schmidt AE, Blinder MA
    ASCP CheckSample: Clinical Chemistry 2012;52(1)
  • Cancer- and Chemotherapy-Induced Anemia
    Rodgers GM 3rd, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB 3rd
    J Natl Compr Canc Netw 2012 May;10(5):628-53
  • Abnormalities in Cardiac Structure and Function in Adults With Sickle Cell Disease Are Not Associated With Pulmonary Hypertension
    Knight-Perry JE, de Las Fuentes L, Waggoner AD, Hoffmann RG, Blinder MA, Davila-Roman VG, Field JJ
    J Am Soc Echocardiogr 2011 Nov;24(11):1285-90
  • Improvements in Haemolysis and Indicators of Erythrocyte Survival Do Not Correlate With Acute Vaso-Occlusive Crises in Patients With Sickle Cell Disease: A Phase III Randomized, Placebo-Controlled, Double-Blind Study of the Gardos Channel Blocker Senicapoc (ICA-17043)
    Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, Smith WR, Galacteros F, Kutlar A, Hull JH, Stocker JW; ICA-17043-10 Study Investigators
    Br J Haematol 2011 Apr;153(1):92-104
  • Recurrent, Severe Wheezing Is Associated With Morbidity and Mortality in Adults With Sickle Cell Disease
    Cohen RT, Madadi A, Blinder MA, Debaun MR, Strunk RC, Field JJ
    Am J Hematol 2011 Sep;86(9):756-61
  • Smoking Is Associated With an Increased Risk of Acute Chest Syndrome and Pain Among Adults With Sickle Cell Disease
    Cohen RT, DeBaun MR, Blinder MA, Strunk RC, Field JJ
    Blood 2010 May 6;115(18):3852-4
  • Commentary
    Blinder MA
    Clin Chem 2010 Jan;56(1):19-20
  • Sustained Response With Rituximab in Patients With Thrombotic Thrombocytopenic Purpura: A Report of 13 Cases and Review of the Literature
    Ling HT, Field JJ, Blinder MA
    Am J Hematol 2009 Jul;84(7):418-21
  • Urinary Cysteinyl Leukotriene E4 Significantly Increases During Pain in Children and Adults With Sickle Cell Disease
    Field JJ, Strunk RC, Knight-Perry JE, Blinder MA, Townsend RR, DeBaun MR
    Am J Hematol 2009 Apr;84(4):231-3
  • Urinary Cysteinyl Leukotriene E(4) Is Associated With Increased Risk for Pain and Acute Chest Syndrome in Adults With Sickle Cell Disease
    Field JJ, Krings J, White NL, Yan Y, Blinder MA, Strunk RC, Debaun MR
    Am J Hematol 2009 Mar;84(3):158-60
  • Eculizumab, a Terminal Complement Inhibitor, Improves Anaemia in Patients With Paroxysmal Nocturnal Haemoglobinuria
    Schubert J, Hillmen P, Röth A, Young NS, Elebute MO, Szer J, Gianfaldoni G, Socié G, Browne P, Geller R, Rother RP, Muus P; TRIUMPH Study Investigators: Mills A, Norman J, Van Den Neste E, Larratt L, Turner A, Hamilton MA, Dührsen U, Ganser A, Montemurro M, Rio B, Bacigalupo A, Luzzatto L, Antonioli E, Mannelli F, Bosi A, Rodeghieroa F, Rotoli B, Alfinito F, Zanella A, Nillson PG, Wahlin A, Samuelsson J, Lundberg LG, Andersson P, Hill A, McMullin MF, Bessler M, Andritsos L, Blinder M, Devine S, Herrmann R, Castro-Malaspina H, Araten D, Coutre S, de Castro C 3rd, Stone E, Konkle B, Kuter D, Lichtin A, Moskovits T, Raphael BG, Amorosi E, Hymes KB, Cook P, Nelson R, Paquette R, Siegel R, Savani B, Chan J, Quinn-Senger K
    Br J Haematol 2008 Jun;142(2):263-72
  • Reticulocyte Hemoglobin Content
    Mast AE, Blinder MA, Dietzen DJ
    Am J Hematol 2008 Apr;83(4):307-10
  • Laparoscopic Versus Open Abdominal Surgery in Children With Sickle Cell Disease Is Associated With a Shorter Hospital Stay
    Goers T, Panepinto J, Debaun M, Blinder M, Foglia R, Oldham KT, Field JJ
    Pediatr Blood Cancer 2008 Mar;50(3):603-6
  • Copper Deficiency: An Important Consideration in the Differential Diagnosis of Myelodysplastic Syndrome
    Fong T, Vij R, Vijayan A, DiPersio J, Blinder M
    Haematologica 2007 Oct;92(10):1429-30
  • Rituximab for the Treatment of Patients With Very High-Titre Acquired Factor VIII Inhibitors Refractory to Conventional Chemotherapy
    Field JJ, Fenske TS, Blinder MA
    Haemophilia 2007 Jan;13(1):46-50
  • Shoulder Arthroplasty in Sickle Cell Patients With Humeral Head Avascular Necrosis
    Lau MW, Blinder MA, Williams K, Galatz LM
    J Shoulder Elbow Surg 2007 Mar-Apr;16(2):129-34
  • (18)F-FDG-PET-Facilitated Diagnosis of Lymphoma Presenting With Fever of Unknown Origin and Cold Agglutination
    Krem MM, Pan L, Blinder MA
    Leuk Lymphoma 2007 Mar;48(3):619-22
  • Considerations in the Evaluation of Haemophilia Patients for Short-Term Prophylactic Therapy: A Paediatric and Adult Case Study
    Luchtman-Jones L, Valentino LA, Manno C
    Haemophilia 2006 Jan;12(1):82-6
  • Immunosuppressive Therapy for Acute Porphyria: Safety and Efficacy in a Patient With Bone Marrow Failure
    Field JJ, Giannone L, Bessler M, Blinder MA
    Pharmacotherapy 2006 Nov;26(11):1662-6
  • Subcutaneous Lepirudin for Heparin-Induced Thrombocytopenia and When Other Anticoagulants Fail: Illustrative Cases
    Deitcher SR, Ngengwe R, Kaplan R, Liebman H, Kaplan K, Blinder M
    Clin Adv Hematol Oncol 2004 Jun;2(6):382-4
  • Dominant Factor XI Deficiency Caused by Mutations in the Factor XI Catalytic Domain
    Kravtsov DV, Wu W, Meijers JC, Sun MF, Blinder MA, Dang TP, Wang H, Gailani D
    Blood 2004 Jul 1;104(1):128-34
  • Hemostatic Complications Associated With Paraproteinemias
    Eby C, Blinder M
    Curr Hematol Rep 2003 Sep;2(5):388-94
  • Cancer and Venous Thromboembolism
    Kommareddy A, Blinder MA
    Contemporary Oncology 2003;1:1-10
  • Remission of Chronic Thrombotic Thrombocytopenic Purpura After Treatment With Cyclophosphamide and Rituximab
    Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA
    Ann Intern Med 2003 Jan 21;138(2):105-8
  • Clinical Utility of the Reticulocyte Hemoglobin Content in the Diagnosis of Iron Deficiency
    Mast AE, Blinder MA, Lu Q, Flax S, Dietzen DJ
    Blood 2002 Feb 15;99(4):1489-91
  • Extreme Warfarin Sensitivity in Siblings Associated With Multiple Cytochrome P450 Polymorphisms
    Tabrizi AR, McGrath SD, Blinder MA, Buchman TG, Zehnbauer BA, Freeman BD
    Am J Hematol 2001 Jun;67(2):144-6
  • Successful Electroconvulsive Therapy Given to a Patient With Von Willebrand's Disease
    Sincoff RC, Giuffra LA, Blinder MA, Isenberg KE
    J ECT 2000 Mar;16(1):68-70
  • Acute Promyelocytic Leukemia With Additional Chromosomal Abnormalities and Absence of Auer Rods
    Kaleem Z, Watson MS, Zutter MM, Blinder MA, Hess JL
    Am J Clin Pathol 1999 Jul;112(1):113-8
  • Donor-Derived Acute Promyelocytic Leukemia in a Liver-Transplant Recipient
    Bodo I, Peters M, Radich JP, Hess J, Blinder M, Watson MS, Van Rheeden R, Natarajan S, Lowell JA, Brown R, DiPersio J, Adkins D
    N Engl J Med 1999 Sep 9;341(11):807-13
  • HPLC Detection of Fetal Blood in Meconium: Improved Sensitivity Compared With Qualitative Methods
    Chen D, Wilhite TR, Smith CH, Blinder MA, Landt M
    Clin Chem 1998 Nov;44(11):2277-80
  • Allosteric Effects of a Monoclonal Antibody Against Thrombin Exosite II
    Colwell NS, Blinder MA, Tsiang M, Gibbs CS, Bock PE, Tollefsen DM
    Biochemistry 1998 Oct 27;37(43):15057-65
  • A 19-Year-Old Woman With Severe Anemia [Editorial]
    Abbey E, Gutierrez F, Chaplin H, Blinder M, Lacy J, Storch G, Clutter W, Atkinson J
    Am J Med 1998;104:200-9
  • Clinical Utility of the Soluble Transferrin Receptor and Comparison With Serum Ferritin in Several Populations
    Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG
    Clin Chem 1998 Jan;44(1):45-51
  • Diabetes and Epistaxis in a 57-Year-Old Man [Editorial]
    Clouse R, Eagar G, Blinder MA, Chaplin D, Kilo C, Gersell D, White H, Atkinson J
    Am J Med 1997;103:74-82
  • Identification of a Monoclonal Thrombin Inhibitor Associated With Multiple Myeloma and a Severe Bleeding Disorder
    Colwell NS, Tollefsen DM, Blinder MA
    Br J Haematol 1997 Apr;97(1):219-26
  • Multimodality Therapy of an Acquired Factor V Inhibitor
    Fu YX, Kaufman R, Rudolph AE, Collum SE, Blinder MA
    Am J Hematol 1996 Apr;51(4):315-8
  • Role of Lysine 173 in Heparin Binding to Heparin Cofactor II
    Whinna HC, Blinder MA, Szewczyk M, Tollefsen DM, Church FC
    J Biol Chem 1991 May 5;266(13):8129-35
  • Complete Nucleotide Sequence of the Gene for Human Heparin Cofactor II and Mapping to Chromosomal Band 22q11
    Herzog R, Lutz S, Blin N, Marasa JC, Blinder MA, Tollefsen DM
    Biochemistry 1991 Feb 5;30(5):1350-7
  • Substitution of Arginine for Leu444 in the Reactive Site of Heparin Cofactor II Enhances the Rate of Thrombin Inhibition
    Derechin VM, Blinder MA, Tollefsen DM
    J Biol Chem 1990 Apr 5;265(10):5623-8
  • Site-Directed Mutagenesis of Arginine 103 and Lysine 185 in the Proposed Glycosaminoglycan-Binding Site of Heparin Cofactor II
    Blinder MA, Tollefsen DM
    J Biol Chem 1990 Jan 5;265(1):286-91
  • Heparin Cofactor IIOslo. Mutation of Arg-189 to His Decreases the Affinity for Dermatan Sulfate
    Blinder MA, Andersson TR, Abildgaard U, Tollefsen DM
    J Biol Chem 1989 Mar 25;264(9):5128-33
  • Relapse of Acute Leukemia After Marrow Transplantation: Natural History and Results of Subsequent Therapy
    Mortimer J, Blinder MA, Schulman S, Appelbaum FR, Buckner CD, Clift RA, Sanders JE, Storb R, Thomas ED
    J Clin Oncol 1989 Jan;7(1):50-7
  • Heparin Cofactor II: cDNA Sequence, Chromosome Localization, Restriction Fragment Length Polymorphism, and Expression in Escherichia Coli
    Blinder MA, Marasa JC, Reynolds CH, Deaven LL, Tollefsen DM
    Biochemistry 1988 Jan 26;27(2):752-9
  • Comparison of Double Beta Lactam Antibiotics With Ticarcillin, Tobramycin and Cefazolin in Febrile Neutropenic Patients
    Mortimer J, Blinder M, Black D, Kwok K, Miller S, Kirby W
    Curr Ther Res 1987;42:25-33
  • Brain Metastasis From Esophageal Carcinoma
    Averbuch SD, Blinder MA
    CA Cancer J Clin 1983 May-Jun;33(3):164-6
  • The Action of Thrombin on Peptide P-Nitroanilide Substrates. Substrate Selectivity and Examination of Hydrolysis Under Different Reaction Conditions
    Lottenberg R, Hall JA, Blinder M, Binder EP, Jackson CM
    Biochim Biophys Acta 1983 Feb 15;742(3):539-57

Book Chapters

  • Hematologic Disorders and Transfusion Therapy
    Zhou A, Ferraro F, Jackups R, Blinder M
    In: The Washington Manual of Medical Therapeutics, 36th Edition (Crees Z, Fritz C, Heudebert A, Noe J, Rengarajan A, Wang X, editors), Wolters-Kluwer, Philadelphia, 2020
  • Hypercoagulable States
    Despotovic VN, Blinder MA
    In: The Washington Manual of Critical Care, 3rd Edition (Kollef MH, Isakow W, Burks AC, Despotovic V, eds), Wolters Kluwer 2017; pp 570-577
  • Transfusion Practices
    Despotovic VN, Blinder MA
    In: The Washington Manual of Critical Care, 3rd Edition (Kollef MH, Isakow W, Burks AC, Despotovic V, eds), Wolters Kluwer 2017; pp 562-569
  • Hematologic Disorders and Transfusion Therapy
    Zhou A, Regenbogen T, Jackups R, Blinder M
    In: The Washington Manual of Medical Therapeutics, 35th Edition (Bhat P, Dretler A, Gdowski M, Ramgopal R, Williams D, eds), Lippincott Walters Kluwer, 2016
  • Hematologic Disorders and Transfusion Therapy
    Jackups R, Sanfilippo K, Wang T-Z, Blinder M
    In: The Washington Manual of Medical Therapeutics, 34th Edition (Godara H, Hirbe A, Nassif M, Otepka H, Rosenstock A, eds), Lippincott Williams & Wilkins, 2013
  • Hematologic Diseases
    Rangwala R, Blinder M
    In: The Washington Manual of Outpatient Internal Medicine (DeFer TM, Brisco MA, Mullur RS, eds), Lippincott Williams & Wilkins, 2010
  • Anemia and Transfusion Therapy
    Rangwala R, Blinder M
    In: The Washington Manual of Medical Therapeutics, 33rd Edition (Foster C, Mistry NF, Peddi PF, Sharma S, eds), Lippincott Williams & Wilkins, 2010
  • Approach to Venous Thromboembolism
    Blinder MA, Young VL
    In: Patient Safety in Plastic Surgery (VL Young, R Botney, eds), Quality Medical Publishing, Inc., St. Louis, 2009; pp 279-310
  • Anemia and Transfusion Therapy
    Field J, Blinder MA
    In: The Washington Manual of Medical Therapeutics, 32nd Edition (D Cooper, A Kranik, S Lubner, H Pero, eds), 2007
  • Von Willebrand Disease
    Sadler JE, Blinder MA
    In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, Fifth Edition (RW Colman, J Hirsh, VJ Marder, AW Clowes, JN George, eds.) Lippincott Williams & Wilkins, Philadelphia, 2006; pp. 905-921
  • Hemostasis and Transfusion Therapy
    Kelleher CM, Curci JA, Blinder MA
    In: The Washington Manual of Surgery, Fourth Edition, 2005; pp. 88-110
  • Anemia and Transfusion Therapy
    Blinder MA, Andritsos L
    In: The Washington Manual of Medical Therapeutics, 31st Edition, 2004; pp 423-439
  • Hematology
    Goodnough LT, Blinder MA
    In: The Washington Manual of Ambulatory Therapeutics, 2002; pp. 323-43
  • Coagulation Disorders in Cancer
    Blinder MA, Behl R
    In: The Washington Manual of Oncology, 2002; pp 441-447
  • Anemia and Transfusion Therapy
    Blinder MA
    In: The Washington Manual of Medical Therapeutics, 30th Edition, 2001; pp 413-428
  • Von Willebrand Disease: Diagnosis, Classification and Treatment
    Sadler JE, Blinder MA
    In: Hemostasis and Thrombosis, 4th Edition (Colman R, Hirsh J, Marder V, Salzman E, eds), 2000; pp 825-837
  • Heparin
    Crowther MA, Ginsberg JS, Tollefsen DM, Blinder MA
    In: Hematology: Basic Principles and Practice, 3rd Edition, 2000; pp 2046-56
  • Hematologic Diseases
    Blinder MA
    In: Clinical Maternal-Fetal Medicine (Winn HN, Hobbins JC, Eds), Parthenon Publishing, Carnforth, UK, 2000; pp 437-54
  • Hemostasis and Transfusion Therapy
    Curci JA, Allen BT, Blinder MA
    In: Washington University Manual of Surgery, 2nd Edition, 1999; pp 60-78
  • Anemia and Transfusion Therapy
    Blinder MA
    In: The Washington Manual of Medical Therapeutics, 29th Edition, 1998; pp 360-374
  • Hematologic Problems
    Blinder MA
    In: Manual of HIV Therapeutics 1st Edition, 1997; pp 158-164
  • Medical Management of Malignant Disease
    Mortimer JE, Blinder MA, Arquette MA
    In: Manual of Medical Therapeutics, 28th Edition 1995;418-436
  • Anemia and Transfusion Therapy
    Blinder MA
    In: Manual of Medical Therapeutics 28th Edition 1995;402-417
  • Heparin
    Tollefsen DM, Blinder MA
    In: Hematology: Basic Principles and Practice. 2nd Edition 1995; 1802-1813
  • Medical Management of Malignancy
    Mortimer JE, Blinder MA, Arquette MA
    In: Manual of Medical Therapeutics, 27th Edition 1992; 356-374